MOESM5 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Lang, Liwei; Shay, Chloe; Zhao, Xiangdong; Xiong, Yuanping; Wang, Xuli; Teng, Yong

doi:10.6084/m9.figshare.11329151.v1

13045_2019_827_MOESM5_ESM.docx (3.07 MB)

MOESM5 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

journal contribution

posted on 2019-12-06, 04:44 authored by Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang, Yong Teng

Additional file 5: Figure S5. Histology examination of tissues taken from mouse major organs (heart, intestine, kidney, liver, lung and spleen) at the endpoint of each indicated treatment.

Funding

National Institute of Dental and Craniofacial Research

History

Usage metrics

Keywords

HNSCC Src, AKT Saracatinib Capivasertib Co-delivery nanoparticles Synergistic effects

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM5 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Funding

National Institute of Dental and Craniofacial Research

History

Usage metrics

Categories

Keywords

Licence

Exports